

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q83408

Kousuke TANI, et al.

Appln. No.: 10/506,536

Group Art Unit: 1626

Confirmation No.: 1208

Examiner: Susannah Lee CHUNG

Filed: September 3, 2004

For: 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE
COMPOUND AS ACTIVE INGREDIENT

SECOND REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ATTN: Office of Initial Patent Examination
Filing Receipt Correction
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


We enclose a copy of the Official Filing Receipt for the above-identified application and request the following correction(s):

Power of Attorney: The patent practitioners associated with Customer Number 23373

Foreign Applications: JAPAN 2003-13447 01/22/2003

Verification for the requested correction(s) is indicated on the Declaration and Power of Attorney for Utility or Design Patent Applications filed September 3, 2004.

Respectfully submitted,


Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550
65565
CUSTOMER NUMBER

Date: April 11, 2008



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/506,536	09/03/2004	1615	920	Q83408		20	1

CONFIRMATION NO. 1208

23373
 SUGHRUE MION, PLLC
 2100 PENNSYLVANIA AVENUE, N.W.
 SUITE 800
 WASHINGTON, DC 20037

FILING RECEIPT



OC000000015178792

Date Mailed: 02/17/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Kousuke Tani, Mishima-gun, JAPAN; ✓
 Kaoru Kobayashi, Mishima-gun, JAPAN; ✓
 Toru Maruyama, Mishima-gun, JAPAN; ✓
 Tohru Kambe, Mishima-gun, JAPAN; ✓
 Mikio Ogawa, Mishima-gun, JAPAN; ✓
 Tsutomu Shiroya, Mishima-gun, JAPAN; ✓

Power of Attorney:

Mark Boland--32197
 Jeffrey Schmidt--41574

The patent practitioners associated
 with Customer Number 23373

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/02478 03/04/2003 ✓

Foreign Applications

JAPAN 2002-58487 03/05/2002 ✓
 JAPAN 2002-216567 07/25/2002 ✓
 JAPAN 2003-13447 01/22/2002

01/22/2003

Projected Publication Date: 05/26/2005.

Non-Publication Request: No

Early Publication Request: No

Title

8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND
AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT

the application of which



is attached hereto

OR



was filed on March 4, 2003 as United States
Application Number or PCT International Application Number
PCT/JP03/02478 (Confirmation No. _____),
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part application(s), material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date	Priority Claimed	
			Yes	No
P. 2002-58487	Japan	March 5, 2002	<input checked="" type="checkbox"/>	<input type="checkbox"/>
P. 2002-216567	Japan	July 25, 2002	<input checked="" type="checkbox"/>	<input type="checkbox"/>
P. 2003-13447	Japan	January 22, 2003	<input checked="" type="checkbox"/>	<input type="checkbox"/>

I hereby claim domestic priority benefits under 35 United States Code §120 of any United States application(s), §119(e) of any United States provisional application(s), or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. or International Application Number(s)	U.S. or International Filing Date	Status
---	-----------------------------------	--------

I hereby appoint all attorneys of **SUGHRUE MION, PLLC** who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.



23373

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR:				
Given Name (first and middle [if any]) Kousuke		Family Name or Surname TANI		
Inventor's Signature <i>Kousuke Tani</i>		Date August 30, 2004		
Residence: City	Mishima-gun	State	Osaka	Country Japan
Citizenship Japan				
c/o MINASE RESEARCH INSTITUTE, ONO PHARMACEUTICAL CO., LTD.,				
Mailing Address: 1-1, Sakurai 3-chome, Shimamoto-cho				
City	Mishima-gun	State	OSAKA	Zip 618-8585
		Country JAPAN		
NAME OF SECOND INVENTOR:				
Given Name (first and middle [if any]) Kaoru		Family Name or Surname KOBAYASHI		
Inventor's Signature <i>Kaoru Kobayashi</i>		Date August 30, 2004		
Residence: City	Mishima-gun	State	Osaka	Country Japan
Citizenship Japan				
c/o MINASE RESEARCH INSTITUTE, ONO PHARMACEUTICAL CO., LTD.,				
Mailing Address: 1-1, Sakurai 3-chome, Shimamoto-cho				
City	Mishima-gun	State	OSAKA	Zip 618-8585
		Country JAPAN		
NAME OF THIRD INVENTOR:				
Given Name (first and middle [if any]) Toru		Family Name or Surname MARUYAMA		
Inventor's Signature <i>Toru Maruyama</i>		Date August 30, 2004		
Residence: City	Mishima-gun	State	Osaka	Country Japan
Citizenship Japan				
c/o MINASE RESEARCH INSTITUTE, ONO PHARMACEUTICAL CO., LTD.,				
Mailing Address: 1-1, Sakurai 3-chome, Shimamoto-cho				
City	Mishima-gun	State	OSAKA	Zip 618-8585
		Country JAPAN		
NAME OF FOURTH INVENTOR:				
Given Name (first and middle [if any]) Tohru		Family Name or Surname KAMBE		
Inventor's Signature <i>Tohru Kambe</i>		Date August 30, 2004		
Residence: City	Mishima-gun	State	Osaka	Country Japan
Citizenship Japan				
c/o MINASE RESEARCH INSTITUTE, ONO PHARMACEUTICAL CO., LTD.,				
Mailing Address: 1-1, Sakurai 3-chome, Shimamoto-cho				
City	Mishima-gun	State	OSAKA	Zip 618-8585
		Country JAPAN		
NAME OF FIFTH INVENTOR:				
Given Name (first and middle [if any]) Mikio		Family Name or Surname OGAWA		
Inventor's Signature <i>Mikio OGAWA</i>		Date August 30, 2004		
Residence: City	Mishima-gun	State	Osaka	Country Japan
Citizenship Japan				
c/o MINASE RESEARCH INSTITUTE, ONO PHARMACEUTICAL CO., LTD.,				
Mailing Address: 1-1, Sakurai 3-chome, Shimamoto-cho				
City	Mishima-gun	State	OSAKA	Zip 618-8585
		Country JAPAN		

NAME OF SIXTH INVENTOR:				
Given Name (first and middle [if any])		Family Name or Surname		
Tsutomu		SHIROYA		
Inventor's Signature			Date	
<i>Tsutomu Shiroya</i>			August 30, 2004	
Residence: City	Mishima-gun	State	Osaka	Country Japan
Citizenship Japan				
c/o MINASE RESEARCH INSTITUTE, ONO PHARMACEUTICAL CO., LTD.,				
Mailing Address: 1-1, Sakurai 3-chome, Shimamoto-cho				
City	Mishima-gun	State	OSAKA	Zip 618-8585
				Country JAPAN
NAME OF SEVENTH INVENTOR:				
Given Name (first and middle [if any])		Family Name or Surname		
Inventor's Signature			Date	
Residence: City		State	Country	Citizenship
Mailing Address:				
City		State	Zip	Country
NAME OF EIGHTH INVENTOR:				
Given Name (first and middle [if any])		Family Name or Surname		
Inventor's Signature			Date	
Residence: City		State	Country	Citizenship
Mailing Address:				
City		State	Zip	Country
NAME OF NINTH INVENTOR:				
Given Name (first and middle [if any])		Family Name or Surname		
Inventor's Signature			Date	
Residence: City		State	Country	Citizenship
Mailing Address:				
City		State	Zip	Country
NAME OF TENTH INVENTOR:				
Given Name (first and middle [if any])		Family Name or Surname		
Inventor's Signature			Date	
Residence: City		State	Country	Citizenship
Mailing Address:				
City		State	Zip	Country